Onco360® Partners with Shorla Oncology for IMKELDI® Oral Solution
Onco360® Has Been Selected as a National Specialty Pharmacy Provider for IMKELDI® (imatinib) Oral Solution
Image: Benzinga
Onco360®, a leading independent specialty pharmacy based in Louisville, Kentucky, has been chosen by Shorla Oncology to provide IMKELDI® (imatinib) Oral Solution, a treatment for various forms of leukemia and other rare diseases. This partnership aims to enhance patient access and adherence to therapy.
- 01Onco360® has been selected by Shorla Oncology to provide IMKELDI® (imatinib) Oral Solution.
- 02IMKELDI® is indicated for several conditions including Philadelphia-positive chronic myeloid leukemia and aggressive systemic mastocytosis.
- 03The oral solution is strawberry-flavored and designed to facilitate accurate dosing for both adults and children.
- 04Onco360® is the largest independent oncology pharmacy in the U.S., founded in 2003.
- 05The pharmacy aims to improve patient adherence and outcomes through this partnership.
Advertisement
In-Article Ad
Onco360®, headquartered in Louisville, Kentucky, has been named a pharmacy partner by Shorla Oncology for the distribution of IMKELDI® (imatinib) Oral Solution. This medication is approved for the treatment of various conditions, including newly diagnosed Philadelphia-positive chronic myeloid leukemia (Ph+ CML), acute lymphoblastic leukemia (Ph+ ALL), and other rare diseases. Benito Fernandez, Chief Commercial Officer of Onco360®, expressed pride in partnering with Shorla Oncology to enhance patient access to this vital oral solution. IMKELDI® is a strawberry-flavored liquid formulation that addresses administration challenges, making it suitable for both adult and pediatric patients. Onco360® is recognized as the largest independent oncology pharmacy in the United States, established to meet the specialized needs of oncologists, patients, and healthcare providers. The company operates through a network of accredited pharmacies, ensuring quality service nationwide.
Advertisement
In-Article Ad
The partnership is expected to enhance access to an important treatment for various cancers and rare diseases, benefiting patients who require these therapies.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the availability of oral treatments for chronic diseases?
Connecting to poll...
Read the original article
Visit the source for the complete story.